Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)
Australian & New Zealand Children's Haematology/Oncology Group
ITM Solucin GmbH
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
Institut Curie
Barbara Ann Karmanos Cancer Institute
Rigshospitalet, Denmark
Miltenyi Biomedicine GmbH
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
National Cancer Institute (NCI)
EMD Serono
St. Jude Children's Research Hospital
Catalysis SL
UNICANCER
Norwegian University of Science and Technology
National Cancer Institute (NCI)
Children's Hospital Los Angeles
OHSU Knight Cancer Institute
Northwestern University
M.D. Anderson Cancer Center
Northwestern University
University of Texas Southwestern Medical Center
Radiation Therapy Oncology Group
The Methodist Hospital Research Institute
OHSU Knight Cancer Institute
Memorial Sloan Kettering Cancer Center
City of Hope Medical Center
Dana-Farber Cancer Institute
Children's Oncology Group
University of South Florida
Children's Oncology Group
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Children's Oncology Group
Novartis
Duke University
Asan Medical Center
City of Hope Medical Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)